Wilms' tumor protein (—KTS) modulates renin gene transcription  by Steege, Andreas et al.
see commentary on page 411
Wilms’ tumor protein (KTS) modulates renin gene
transcription
Andreas Steege1,2,4, Michael Fa¨hling1, Alexander Paliege3, Anja Bondke1, Karin M. Kirschner1,
Peter Martinka1, Charlotte Kaps2,4, Andreas Patzak1, Pontus B. Persson1, Bernd J. Thiele1, Holger Scholz1
and Ralf Mrowka1,4
1Institut fu¨r Physiologie CCM, Charite´––Universita¨tsmedizin Berlin, Berlin, Germany; 2Institut fu¨r Biologie, Freie Universita¨t Berlin, Berlin,
Germany; 3Institut fu¨r Vegetative Anatomie, Charite´––Universita¨tsmedizin Berlin, Berlin, Germany and 4Institut fu¨r Physiologie CCM,
AG Systems Biology––Computational Physiology, Charite´––Universita¨tsmedizin Berlin, Berlin, Germany
Renin plays a crucial role in the control of various
physiological processes such as blood pressure and body
fluid homeostasis. Here, we show that a splice variant of the
Wilms’ tumor protein lacking three amino acids WT1(KTS)
suppresses renin gene transcription. Using bioinformatics
tools, we initially predicted that a WT1-binding site exists in
a regulatory region about 12 kb upstream of the renin
promoter; this was confirmed by reporter gene assays and
gel shift experiments in heterologous cells. Co-expression of
Wt1 and renin proteins was found in rat kidney sections,
mouse kidney blood vessels, and a cell line derived from the
juxtaglomerular apparatus that produces renin. Knockdown
of WT1 protein by siRNA significantly increased the cellular
renin mRNA content, while overexpression of WT1(KTS)
reduced renin gene expression in stable and transiently
transfected cells. A mutant WT1(KTS) protein found in
Wilms’ tumors failed to suppress renin gene reporter activity
and endogenous renin expression. Our findings show that
renin gene transcription is regulated by the WT1(KTS)
protein and this may explain findings in patients with WT1
gene mutations of increased plasma renin and hypertension.
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The aspartyl protease renin cleaves the decapeptide angiotensin I
from its precursor molecule angiotensinogen. Angiotensin I
is subsequently transformed by the angiotensin-converting
enzyme to angiotensin II, which is one of the most important
regulators of blood pressure and electrolyte balance.1 The
formation of angiotensin I by the proteolytic activity of renin
is the rate-limiting step in the human renin–angiotensin
system.2 Renin expression is regulated at different levels
including transcriptional control3 and post-transcriptional
mechanisms, for example, mRNA stability and translational
efficiency.4,5 Additional pathways regulate protein release
from the renin-producing cells into the extracellular space.6
The transcriptional control of the human renin gene is
mainly attributed to three upstream regions. The interaction
of transcription factors (for example, CREB, Notch, cyto-
kines) with specific binding sites in the promoter appears
to be most important for the transcriptional regulation of
renin expression in mouse7–9 and humans.10 Some aspects
of the tissue-specific transcriptional control are regulated
through a second sequence motif. This so-called chorionic
enhancer resides approximately 5700 bp upstream of the
transcription start site11 in the human renin gene. Its
in vivo importance is controversially discussed.12 As a third
important region, the renal enhancer is localized approxi-
mately 12 kb upstream of the transcription initiation point.13
This region is of crucial importance by modulating renin
expression, for example, in response to active vitamin D3
metabolites.14 The renal enhancer is part of a 4-kb sized
region, spanning from 12 to 15 kb upstream of the trans-
cription start site, and shows a very high conservation among
mammals.15 The data gathered hitherto indicate that there
are more regulatory sites in this region modulating renin
gene expression.16 Recent studies show that the hRENc
region might be of great importance for renin gene regulation
in vivo.17,18
Alterations in renin expression may result from muta-
tions of trans-factors that interact with cis-regulatory
elements in the renin gene.19 In this regard, mutations of
the Wilms’ tumor suppressor WT1 appear to be of particular
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importance. The Wilms’ tumor gene WT1 on human
chromosome 11p1320 encodes a Kruppel-like zinc-finger
protein with a high degree of homology to the early growth
response (EGR) family of transcription factors.21 Mutations
in the human WT1 locus can be associated with Denys-
Drash22 and WAGR syndrome.23 Denys-Drash patients suffer
from Wilms’ tumor (nephroblastoma), pseudohermaphro-
ditism, and other urogenital abnormalities resulting in renal
failure.24 Remarkably, these individuals frequently have
elevated plasma renin levels25 and may subsequently develop
arterial hypertension.26,27 Most of the known Denys-Drash
mutations affect exon 9 of the WT1 gene, which encodes the
third zinc-finger of the WT1 protein.28 The DNA-binding
affinity of the mutated WT1 protein is strongly reduced
compared to the normal molecule.29 Patients with WAGR
syndrome exhibit severe developmental disorders consisting
of Wilms’ tumor, aniridia, genitourinary malformations, and
mental retardation.23 Alternative splicing of the WT1 mRNA
can lead to the insertion of three additional amino acids
(lysine, threonine, and serine (KTS)) between zinc-finger
three and four of the protein.30 Lack of the WT1(þKTS)
molecule is found in Frasier syndrome,31 an abnormality
characterized by male pseudohermaphroditism and progres-
sive glomerulopathy.32 The WT1(þKTS) protein has RNA-
binding affinity and presumably acts on mRNA splicing.33
The WT1(KTS) molecule, which lacks the three amino acid
insertion, interacts with GC-rich elements and functions as a
transcription factor. Other specified core binding sites are
the 50-(TCC)n-30 motif
34 and the 50-GG/YGTGGGCG/C-30
sequence.35 Transcriptional control by WT1(KTS) is
crucial in a variety of developmental processes, including
formation of the urogenital system,36 the retina,37 and
hematopoiesis.38
Consistent with the clinical finding of elevated plasma
renin levels in Denys-Drash patients, previous studies
characterized Wilms’ tumors as renin-producing malignan-
cies.39 It is unknown so far whether the enhanced renin
content in Wilms’ tumor is due to stimulated renin gene
transcription resulting from WT1 mutations, or whether it is
secondary to abnormal kidney anatomy. We therefore
investigated a possible direct effect of WT1 on renin gene
transcription, focusing on our previously identified regula-
tory region15 12 kb upstream of the renin promoter.
RESULTS
Several approaches were used to determine whether renin
and Wt1 are co-expressed in the kidneys and renal cells. First,
rat kidney serial sections were tested for the colocalization of
both proteins. As shown in Figure 1, a striking co-expression
of Wt1 and renin is visible in the afferent arterioles of the
adult rat kidney. Consistent with previous reports,40,41 Wt1
immunoreactivity was also seen in glomerular podocytes.
Immunostaining of both podocytes and afferent arterioles
was prevented by pre-incubation of the anti-Wt1 antibody
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Figure 1 | Immunohistochemical localization of Wt1 and renin in the adult rat kidney. An immunoperoxidase staining technique
was applied to mark the Wt1- and renin-expressing cells on two consecutive cryostat sections from adult rat kidney. Note that Wt1
immunoreactivity is present in cells of the afferent arterioles (arrows in b, e) in addition to its previously recognized expression in glomerular
podocytes (arrowheads in b). Renin is detected in the juxtaglomerular region including afferent arterioles (arrows in c, f). No staining is seen
with the use of normal rabbit serum instead of primary antibody (insert in a). The results shown are representative for the nine tissue
sections that were analyzed from three different rats. Original magnifications are  100 (a),  200 (d), and  320 (b, c, e, f) the original,
respectively. Areas shown in the high-power magnifications are indicated on (a, d).
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with specific blocking peptide (see Supplementary material).
Co-expression of the Wt1 and renin genes could also be
demonstrated at the mRNA level in dissected arterioles and
glomeruli from mouse kidneys and, additionally, at the
protein level in As4.1 cells (Figure 2).
To examine whether WT1(KTS) regulates renin gene
expression, we first used an siRNA approach to knock down
Wt1 in murine M15 cells, which strongly express the Wt1
gene. Wt1 silencing caused an approximately fourfold
increase of the cellular renin mRNA content compared
to the control (Figure 3). Furthermore, we isolated protein
from stable Wt1(KTS) transfected human embryonic
kidney (HEK) 293 cells. As shown in Figure 4, permanent
expression of Wt1(KTS) significantly reduced renin protein
by approximately 60% compared to empty vector trans-
fected cells. Likewise, transfection of HEK293 cells with a
WT1(KTS) expression construct significantly decreased
renin mRNA in transient experiments (Figure 5). In contrast,
transient expression of the WT1(KTS)D396G construct,
which carries a dominant-negative Denys-Drash mutation,
had no significant effect on the endogenous renin transcripts
(Figure 5). These findings demonstrate that renin gene
expression in HEK293 cells is inhibited by the WT1(KTS)
protein.
This effect was further analyzed at the molecular level
using a bioinformatical approach to predict potential
WT1(KTS)-binding sites within the upstream region of
the renin gene. As illustrated in Figure 6a, a core binding
sequence for WT1(KTS) is located approximately 11.1 kb
upstream of the transcription start point. Conservation
(ClustalW) and the information content of each nucleo-
tide (sequence logo technique) within the WT1 core
sequence indicate a potential functional importance of
this WT1(KTS)-binding site and its flanking regions
(Figure 6b).
To verify the interaction of WT1(KTS) with the
predicted DNA element and its ability to regulate the renin
promoter, we performed reporter gene assays. For this
purpose, a B700-bp fragment of the hRENc region, which
included the putative WT1(KTS)-binding site, was cloned
upstream of the canonical renin promoter and the effect of
WT1(KTS) on the activity of this reporter construct was
investigated in transient co-transfection experiments. The
vector including the B700-bp fragment in addition to the
canonical renin promoter is assigned pGL3-hRENc5.5-RENp,
and the construct containing the canonical renin promoter
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Figure 2 | Detection of Wt1 and renin mRNA and protein
in tissue samples from murine kidney and in the renin
producing juxtaglomerular-derived As4.1 cell line. (a) To
determine the co-expression of Wt1 and renin, total RNA was
extracted from tissue samples and As4.1 cells. After reverse
transcription, the mRNA expression was analyzed using specific
primers for Wt1 and renin. The detection of beta-actin served as a
control. The PCR products by ethidium bromide staining of
agarose gels are shown. In the no-template control no amplicon
was detectable (not shown). The values to the left indicate the
expected sizes (bp) of the PCR fragments demonstrating correct
amplification of the cDNA. (b, c) As4.1 cells were grown on slides.
After reaching 80% confluence, the cells were fixed in methanol/
acetone, and renin (b) and Wt1 (c) proteins were detected with
specific antibodies. DAPI staining was performed to visualize the
cell nuclei.
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Figure 3 | Renin mRNA is increased upon silencing of Wt1 by
siRNA transfection. Wt1 expressing murine M15 cells were
transfected with siRNA targeting Wt1. Total RNA was isolated after
48 h of incubation. After reverse transcription, the relative mRNA
levels were determined by real-time PCR utilizing the DCt method.
All values were normalized to beta-actin transcripts. The relative
changes compared to the control values are shown. Error bars
represent the standard deviations. Experiments were performed
in triplicate.
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Figure 4 | Renin protein is decreased in stable Wt1(KTS)
transfected human embryonic kidney (HEK) 293 cells. HEK293
cells were stably transfected with a Wt1(KTS) expression
construct or empty vector. Cell lysates were separated by
SDS-PAGE and transferred to a nylon-membrane. Proteins were
detected using specific antibodies. Beta-actin served as a loading
control. Each lane represents a pool of three independent
samples. The statistics was calculated from independent
non-pooled western blot samples. Note that forced expression of
Wt1(KTS) reduces renin protein content in the HEK293 cells.
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alone is called pGL3-RENp (Figure 7a). As shown in Figure
7b, forced expression of WT1(KTS) significantly reduced
reporter activity of the pGL3-hRENc5.5-RENp construct
compared to the pGL3-RENp plasmid. Interestingly, the
mutant WT1(KTS)D396G expression construct, which
differs from the normal WT1(KTS) protein by a single
point mutation at position 396, had no significant effect on
reporter gene activity (Figure 7b). Furthermore, deletion of
the predicted WT1(KTS)-binding site in the hRNEc5.5-
region (pGL3-hRENc5.5[WT1del]-RENp) significantly
elevated the basal reporter activity and resulted in a loss
of the inhibitory action of WT1(KTS) (Figure 7b). In
contrast to the WT1(KTS) splice variant, forced expression
of the WT1(þKTS) protein did not significantly change
the activity of the hRENc5.5-RENp reporter construct
(Figure 7c). We observed no significant effects of either
WT1(KTS) or WT1(KTS)D396G on the reporter gene
activity of pGL3-hRENp, which contains the renin promoter
alone (Figure 7d).
These findings indicate that the WT1(KTS) protein can
interact with a cis-element located B12 kb upstream of the
transcription start site in the renin gene and inhibit renin
promoter activity.
To confirm a direct WT1(KTS)–DNA interaction at the
predicted core sequence within the regulatory upstream
element, we performed gel shift analyses with double-
stranded DNA oligonucleotides. As demonstrated in Figure 8,
Wt1(KTS) protein bound to the regulatory element WT1ir
(WT1 interacting region), and this interaction could be
competed with unlabeled oligonucleotide in a concentration-
dependent manner. Specificity of this interaction of
WT1(KTS) with the binding site is indicated by the lack
of competition with unlabeled oligonucleotide carrying a
mutation to prevent Wt1(KTS) binding (WT1irmut)
(Figure 8b). Chromatin immunoprecipitation (ChIP) assay
confirmed the binding of Wt1 to the predicted genomic
region in a more natural chromosomal context (Figure 9).
DISCUSSION
The renin–angiotensin system plays an important role in
many physiological processes such as blood pressure control
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Figure 5 | Transient transfection of WT1(KTS) but not of the
mutated WT1(KTS)D396G protein reduces renin mRNA.
HEK293 cells were transiently transfected with WT1(KTS) or
WT1(KTS)D396G expression vectors. At 24 h later, the cells were
harvested and the RNA was isolated. After reverse transcription,
the relative mRNA levels were measured by real-time PCR and
normalized to beta-actin transcripts utilizing the DCt method. The
means of relative renin mRNA values are shown. The error bars
represent the standard deviation.
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Figure 6 | Schematic illustration of regulatory regions in the renin gene locus. (a) Transcriptional control of the renin gene (renin cds)
is attributed to the promoter, the chorionic enhancer (CoEnh), and the renin enhancer (ReEnh). The human renin conserved region
(hRENc), which contains the WT1(KTS) core binding site TCCCGCCC, was proposed to be important for renin expression.
(b left) Computation of information content and conservation of the WT1(KTS) core binding site. (b right) ClustalW alignment of the
human, chimpanzee, rhesus monkey and mouse sequence containing the WT1(KTS) binding element. Sequences were obtained from
genomic databases. The frame displays the core sequence and asterisks indicate nucleotides, which are conserved in all four species.
The core binding sequence of WT1 is highlighted by black square in the sequence alignment.
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and electrolyte homeostasis.42 Inadequate synthesis and
release of renin may give rise to arterial hypertension43 and
end-organ damage, for example, glomerulosclerosis.44 Renin
gene expression is regulated at different levels, including
transcriptional and post-transcriptional mechanisms.45
Previous studies indicated that the control of renin
transcription is not restricted to the promoter, but involves
additional cis-acting elements in the far-upstream region of
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Figure 7 | WT1(KTS) but not the mutated WT1(KTS)D396G protein stimulates renin promoter activity in the context of an
upstream cis-element. (a) Illustration of the reporter constructs used in the co-transfection experiments. The vector containing the
canonical renin promoter is called pGL3-RENp. The construct pGL3-hRENc5.5-RENp carries a B700 bp upstream regulatory region in
addition to the renin promoter. A third construct, pGL3-hRENc5.5(WT1del)-RENp, carries a WT1-binding site deletion in the upstream
sequence. (b) Reporter gene activity was determined 24 h after co-transfection of HEK293 cells with WT1(KTS) and WT1(KTS)D396G,
respectively. Note that WT1(KTS) but not the Denys-Drash mutant, WT1(KTS)D396G, nor the WT1(þ KTS) protein (c) reduces the activity
of the pGL3-hRENc5.5-RENp reporter construct. WT1(KTS) and WT1(KTS)D396G have no significant effect on pGL3-RENp (d). Each bar
represents the mean value of four independent experiments. Error bars indicate the standard deviation.
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the renin gene.22,46 Our novel findings demonstrate that the
Wilms’ tumor protein WT1 participates in renin gene
regulation. Through binding to aB12 kb upstream sequence,
the transcriptionally active WT1(KTS) protein inhibits
renin promoter activity in co-transfection experiments and
downregulates expression of the endogenous renin gene in
renal cells. These results can provide an explanation for the
sometimes elevated plasma renin levels and arterial hyperten-
sion in patients suffering from Wilms’ tumor.47
Several lines of evidence suggest that the regulatory link
between WT1(KTS) and renin is not limited to cultured
cells but may possibly also be important in intact (renal)
tissue. Thus, renin and Wt1 mRNA were detected in freshly
prepared afferent arterioles and glomeruli from mouse
kidney (Figure 2). Expression of renin in murine glomeruli
is in line with two recent investigations showing the presence
of all molecular components of the renin–angiotensin system
in podocytes of adult kidney.48,49 Furthermore, Wt1 and
renin proteins could be visualized in renal juxtaglomerular-
derived As4.1 cells (Figure 2). Probably the most convincing
proof of the relationship between WT1 and renin is provided
by their co-localization in cells of the juxtaglomerular
apparatus in rat kidneys (Figure 1). Initial studies revealed
that WT1 is highly expressed in the genitourinary system and
mesothelial tissues of the developing embryo.50,51 During
maturation WT1 is downregulated in most organs including
the kidneys, which, according to general belief, express WT1
only in glomerular podocytes. In a previous study, we found
increased Wt1 mRNA and protein levels in the kidneys of rats
that had been exposed to hypoxia.52 Remarkably, hypoxic rats
contained Wt1 not only in the podocytes but also in tubular
epithelial cells in the renal cortex.52 These observations
suggested that, in addition to the glomerular podocytes,
certain cell types, which are derived from common WT1-
positive progenitors, retain their capacity to express WT1 in
the adult organism. By detecting WT1 in renin-producing
cells of the kidneys our present findings provide first evidence
for a novel, so far unrecognized role of WT1 in regulating
renin gene expression. Such function is consistent with
previous studies identifying the area postrema region as a site
of Wt1 expression in the developing brain.50 To be recalled,
this area is considered as a major spot of action of the local
renin–angiotensin system in the central nervous system.
Among the various genes that are regulated by the
WT1 transcription factor is NTRK2, which encodes the
TrkB neurotrophin receptor.53 Interestingly, TrkB expression
predominates at sites of renin expression in the developing
kidney.54 Furthermore, targeted inactivation of Ntrk2 dis-
rupted normal formation of the juxtaglomerular apparatus in
mice.54 These findings raise the possibility that neurotrophins
and their receptors may act as downstream effectors of WT1
in the regulation of the renin–angiotensin system. Given that
WT1 and renin share an overlapping distribution in the
kidney, one may ask the question whether the expression of
both proteins is regulated in a coordinated manner. As a first
approach to resolve this issue, mice were fed either with
furosemide or ramipril to stimulate renin gene expression. As
shown in the Supplementary material to this study, both
treatment protocols increased renin transcripts in the kidneys
several fold, but had no significant effect on Wt1 mRNA
levels. These observations suggest that Wt1 and renin
stimulatory pathways, at least those involving the macula
densa signal and angiotensin-converting enzyme inhibition,
are not closely linked.
The WT1(KTS)-binding site in the renin gene could
be localized in the hRENc region15 in close proximity to the
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renal enhancer,3,17 which has recently been shown to be
important for renin gene expression in vivo.17 The interaction
of WT1 was predicted by the existence of a core binding
motif.55 The WT1(KTS)-binding site TCC(C/T)GCC(C/T)
and its flanking regions are highly conserved between species,
which gives supporting evidence for the functional impor-
tance of this specific cis-element (Figure 6). This prediction
was confirmed by reporter gene experiments and EMSA
(Figures 7 and 8) as well as by a ChIP assay (Figure 9). Our
findings demonstrate that WT1(KTS) serves as a transcrip-
tional repressor of the renin gene through acting on the
hRENc5.5 region rather than having a direct effect on the
renin promoter (Figure 7d). The inhibitory effect was
abrogated with a protein (WT1(KTS)D396G) carrying the
Denys-Drash mutation.
In conclusion, our findings demonstrate a novel mechanism
of renin gene regulation by the Wilms’ tumor transcription
factor WT1. With the use of bioinformatics, we predicted a
highly conserved WT1(KTS)-binding site within a far-
upstream regulatory region (hRENc) of the renin gene. It is
suggested that binding of WT1(KTS) to the identified
cis-element inhibits basal renin promoter activity and regulates
renin gene expression in concert with other transcription
factors. Our data suggest that the high plasma renin levels and
arterial hypertension sometimes seen in Wilms’ tumor
patients47 could be due to the lack of inhibition of renin gene
transcription by the mutant WT1 protein. Further attempts
will be necessary to analyze the role of WT1 in the formation
and function of the juxtaglomerular apparatus of the kidneys.
MATERIALS AND METHODS
Expression vectors
WT1(KTS) pBluescript KS containing the human WT1(KTS)
coding sequence was a generous gift from Prof Manfred Gessler
(Theodor-Boveri-Institut, University of Wu¨rzburg, Wu¨rzburg,
Germany). The coding sequence was cloned into the BspEI and
EcoRV restriction sites of the pIRESpuro2 plasmid (Clontech,
Mountain View, CA, USA) to generate the expression vector
WT1(KTS). To investigate the influence of a mutated WT1
protein, an amino-acid transition at position 396 from aspartic acid
to glycin was inserted into the WT1 expression vector using existing
restriction sites in the coding region and a modified double-
stranded oligo DNA fragment. Expression vectors were named
WT1(KTS) and WT1(KTS)D396G. For further details, see the
Supplementary material.
Forced expression of WT1
To investigate the effects of WT1(KTS) on renin gene expression,
we used stable and transiently transfected HEK293 cells. The
generation of stable HEK293 cells has been previously described.56
HEK293 cells were transiently transfected at 80% confluence with
2 mg of the expression vectors using the FuGENE 6 reagent (Roche,
Mannheim, Germany) according to the manufacturer’s manual.
Reporter gene construction
Firefly luciferase reporter gene constructs were generated using the
pGL3basic (Promega, Mannheim, Germany) vector as a backbone as
described previously.57 The vector, which carried a deletion of the
WT1(KTS)-binding site (position 11,133 to 11,154 bp, acc.
number: AL592114), was assigned pGL3-hRENc5.5[WT1del]-RENp.
Further technical details are provided in the Supplementary material.
Cell culture
HEK293 cells obtained from the American Type Culture Collection
(ATCC no. CRL1573) and stable transfected cell lines were cultured
in Dulbecco’s modified Eagle’s medium (DMEM) high glucose
medium supplemented with 1 mmol/l HEPES (4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid), 50 U/ml penicillin, 50mg/ml
streptomycin, 2 mmol/l L-glutamine, and 10% fetal calf serum
(Biochrom KG, Berlin, Germany). The cells were grown at 371C in
humidified air with 5% CO2.
Reporter gene assays
Experiments were performed in 96-well plates (Greiner, Frick-
enhausen, Germany) as described previously.57 Co-transfections
were carried out with 100 ng of the WT1 expression vectors. See the
Supplementary material for further details.
RNA purification
To investigate changes of the endogenous renin mRNA, HEK293
cells were transiently transfected. At 24 h later, the cells were washed
with ice-cold phosphate-buffered saline (PBS) and the RNA was
isolated using the RNA-Bee reagent (Biozol, Eching, Germany)
according to the manufacturer’s protocol. Accordingly, RNA was
extracted from As4.1 cells and dissected glomeruli and afferent
arterioles from mouse kidney.
Conventional reverse transcription-PCR
cDNA was synthesized from total RNA using SuperScript II Reverse
Transcriptase and random hexamers (Invitrogen, Karlsruhe,
Germany) according to the manufacturer’s instructions. The PCR
reaction was performed in a total volume of 20 ml with 0.2 pmol/ml
of each primer and 2 ml cDNA. PCR for Wt1 and renin was carried
out at 581C annealing temperature with 40 cycles. Published
nucleotide sequences for murine Wt1 (NM_144783), renin
(NM_031192), and beta-actin (NM_007393) were used to design
primers bridging at least one intron. Restriction analysis with DrdI
and HinfI was performed to verify the correct amplicons. PCR
products were visualized on a 1.5% agarose gel.
mRNA quantification by real-time reverse transcription-PCR
Renin mRNA was measured by real-time reverse transcription-PCR
analysis. For this purpose, 2mg of the isolated total RNA was reverse
transcribed using SuperScriptII Reverse Transcriptase and random
hexamers (Invitrogen). Quantitative PCR analysis was performed in
triplicate with the GeneAmp 5700 system (Applied Biosystems,
Darmstadt, Germany) according to the manufacturer’s instructions.
Published sequences for human renin (NM_000537) and beta-actin
(NM_001101) were used to design primers bridging at least one
intron. The expression levels of renin mRNA were normalized to beta-
actin using the DCt method. Parallelism of standard curves of the test
and control was confirmed (see also the Supplementary material).
Electrophoretic mobility shift assay
A double-stranded DNA oligonucleotide representing the predicted
WT1(KTS) interaction region (WT1ir), and mutant oligos were
labeled with 32P g-ATP (7000 Ci/mmol; MP Biomedicals, Eschwege,
Germany) using the terminal T4 polynucleotide kinase (Promega)
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according to the manufacturer’s manual. WT1ir had the sequence
50-GCAGTTCCCGCCCTGTCATTT-30, the sequence of WT1irmut
was 50-GCAGTTCCCGCTTTGTCATTT-30. The labeled DNA frag-
ments were adjusted to 10,000 c.p.m. and incubated with 1.7 mg of
recombinant Wt1(KTS) in EMSA buffer (60 mM HEPES pH 7.9,
20 mM Tris-HCl pH 7.9, 300 mM KCl, 5 mM EDTA) for 30 min on ice.
Unlabeled competing oligonucleotides were added to the binding
reactions between 25- and 200-fold excess. The DNA–protein
complexes were separated by electrophoresis in a 10% polyacryl-
amide gel, and the radioactive signals were detected using the
phosphoimager system (FUJI FILM FLA-3000).
ChIP
ChIP assay was performed in M15 cells, which express Wt1 at high
level. Because of space limitation a detailed protocol of that
technique is attached in the Supplementary material.
Protein isolation and quantification
To investigate the influence of WT1 on the endogenous renin
protein, we isolated cytosolic protein extracts from stable transfected
HEK293 cells. Cells were washed with ice-cold PBS and scraped off
the plates in 1 ml PBS. After centrifugation at 100 g for 5 min, the
cells were resuspended in 150ml lysis buffer containing: 20 mmol/l
Tris, 140 mmol/l NaCl, 1 mmol/l EDTA, 1 mmol/l dithiothreitol, 25%
glycerin, 0.1% SDS, 1 proteinase inhibitor cocktail (Roche),
followed by incubation on ice for 10 min. After incubation, the
samples were centrifuged at 10,000 g for 10 min. Supernatants
containing the cytosolic proteins (S10) were subjected to SDS-PAGE.
Proteins were detected using primary antibodies against renin and
Wt1 (anti-human renin, Acris Antibodies, anti-mouse Wt1; Santa
Cruz, Heidelberg, Germany). Anti-beta-actin antibody (Chemicon,
Hampshire, UK) was used as a loading control (see also the
Supplementary material).
Immunostaining of Wt1 and renin in As4.1 cells
As4.1 cells (ATCC no. CRL-2193) were cultured on cover slides in
DMEM high glucose supplemented with 4 mM L-glutamine, 1.5 g/l
sodium bicarbonate and 10% fetal calf serum (Biochrom KG). The
cells were grown at 371C in humidified air with 5% CO2. Renin and
Wt1 proteins were detected using rabbit anti-renin (kindly provided
by Prof T Inagami) and rabbit anti-Wt1 antibodies (Santa Cruz). See
also the Supplementary material.
Immunostaining of Wt1 and renin in rat kidney sections
Adult male Wistar rats (n¼ 3) weighing between 300 and 350 g were
obtained from the local animal facility and kept on standard diet
and tap water ad libitum. Animals were anesthetized by pentobar-
bital sodium injection (0.06 mg per g body weight i.p.). The
abdominal cavity was opened, and the kidneys were perfused
retrogradely via the abdominal aorta with PBS, pH 7.4, adjusted to
330 mosmol/kg H2O with sucrose. Perfusion fixation was performed
with 3% paraformaldehyde in PBS.58 Kidneys were dissected and
processed for cryostat sectioning in series of 5 mm consecutive
sections for immunohistochemistry. Immunostaining was per-
formed using an immunoperoxidase technique as described53 (see
also the Supplementary material).
siRNA transfection
Wt1 silencing was achieved by siRNA transfection of murine
mesonephros-derived M15 cells. The cells, which were grown in
supplemented (see above) DMEM high glucose medium, were
seeded in six-well plates 24 h before transfection. At 80% confluence,
the cells were incubated with 100 nM murine-specific siRNA
(TargetOn; Dharmacon, Lafayette, CO, USA) against Wt1 using
DharmaFect 1 (Dharmacon) transfection agent according to the
manufacturer’s protocol. After 48 h total RNA was isolated with
the RNA-Bee reagent (Biozol, Eching, Germany).
Isolation of afferent arterioles and glomeruli from mouse
kidneys
Male C57Bl6 mice with body mass between 23 and 27 g were used.
After killing the animals by craniocervical dislocation, the kidneys
were immediately removed and sliced along the cortico-medullary
axis. The afferent arterioles were prepared at 41C in DMEM
containing 0.1% albumin (see Supplementary material).
Biostatistical tests
For the prediction of the WT1-binding site (core sequence:
TCCCKCYC), the TRANSFAC 6.1 program was used.55 The multi-
species alignment was carried out by the ClustalW algorithm.59 The
information content of nucleotides, representing the WT1(KTS)-
binding site, was illustrated using the sequence logo method.60 The
sequence logo method allows the calculation of the information
content of each nucleotide at any position in the sequence, based on
a conservation score.
Statistical analyses
Analysis of variance was applied for comparison of more than two
observations. When appropriate, post hoc tests were performed with
Student’s t-test. The P-value was corrected for multiple comparisons
according to Bonferroni. The null hypothesis was rejected at the 0.05
level. Results are presented as means; error bars represent the
standard deviation.
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